Web-Based Tool for Cardiovascular Care in Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a web-based tool called the CARE-PC Web-Based Application, designed to help men with prostate cancer undergoing androgen deprivation therapy (ADT) understand and manage their heart health. The goal is to improve patient awareness of personal heart risks and provide ways to reduce those risks. Men with prostate cancer who are currently on ADT or will be on it for at least six months are suitable candidates for this trial. Participants will use the tool to learn about their cardiovascular risks and assess its impact on their care.
As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart health management for men with prostate cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this web-based tool is safe for cardiovascular education in prostate cancer patients?
Research has shown that the CARE-PC web app helps men with prostate cancer understand their risk of heart problems. This tool educates users about heart health risks and offers advice on reducing them.
Regarding safety, the app serves purely for learning and information. It doesn't involve taking new medications or undergoing medical procedures, so it poses no physical side effects or risks.
The main goal of this tool is to help prostate cancer patients better understand and manage their heart health. As an educational tool, it is considered very safe for participants.12345Why are researchers excited about this trial?
Researchers are excited about the CARE-PC Web-Based Application because it offers a novel approach to managing cardiovascular health in men with prostate cancer undergoing androgen deprivation therapy (ADT). Unlike traditional treatments which primarily focus on hormone levels, this web-based tool provides personalized cardiovascular care by integrating digital health monitoring and patient education. By leveraging technology, it aims to empower patients to actively participate in their care, potentially improving overall health outcomes and quality of life. This innovative approach could set a new standard in supportive care for prostate cancer patients.
What evidence suggests that this web-based tool is effective for improving cardiovascular care in prostate cancer patients?
Research shows that online tools like the CARE-PC app can help patients better understand their heart health risks. In this trial, the CARE-PC app educates prostate cancer patients about their heart risks while on androgen deprivation therapy (ADT). Early results suggest that digital health tools can help patients manage these risks by providing personalized information and advice. Studies have found that when patients understand their health risks, they are more likely to take steps to reduce them. Overall, the CARE-PC app could play an important role in helping prostate cancer patients maintain heart health.12367
Who Is on the Research Team?
Vivek K. Narayan
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for men over 18 with prostate cancer who are currently on or will start androgen deprivation therapy (ADT) for at least six months. Participants need to be able to read and understand English.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Web-Based Application Participation
Participants use a web-based tool to learn about cardiovascular risks and receive individualized risk estimates and mitigation recommendations
Follow-up
Participants are monitored for changes in cardiovascular care and medication adjustments
What Are the Treatments Tested in This Trial?
Interventions
- CARE-PC Web-Based Application
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vivek Narayan
Lead Sponsor
National Comprehensive Cancer Network
Collaborator